Nebispes (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility, while simultaneously stimulating endothelial nitric oxide synthase. The resulting nitric‑oxide‑mediated vasodilation reduces peripheral resistance and blood pressure, and improves myocardial oxygen supply.

The dosage of Nebispes is individualized by the prescribing clinician based on the patient’s condition, response, and renal function. Typical starting doses may be low and titrated upward, but exact regimens are determined by the healthcare professional.

The safety of nebivolol during pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions are made by the treating physician.

To request Nebispes, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol distinguishes itself by its β1‑selectivity and nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects and improved endothelial function compared with non‑selective beta‑blockers. Clinical efficacy in lowering blood pressure and managing heart failure is comparable, but individual patient response and tolerability guide the choice of therapy.

Nebispes tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Nebispes is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse reactions to nebivolol can include severe bradycardia, heart block, acute bronchospasm in patients with obstructive airway disease, and rare cases of hepatic injury or anaphylaxis. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, jaundice, or rash.

Nebispes is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree atrioventricular block, decompensated heart failure, or uncontrolled asthma/COPD. It should also be used with caution in individuals with severe hepatic or renal impairment.